Soligenix, Inc. (SNGX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Soligenix, Inc. (SNGX) trades at $0.3801 with AI Score 28/100 (Grade F). Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Market cap: $5.63M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 5, 2026Analyst Coverage for SNGX: SNGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNGX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SNGX: 3/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Soligenix, Inc. (SNGX) Healthcare & Pipeline Overview
Soligenix, Inc. is a biopharmaceutical company specializing in the development of treatments for rare diseases and areas of unmet medical need. The company's pipeline focuses on both specialized bio-therapeutics and public health solutions, including a novel photodynamic therapy for cutaneous T-cell lymphoma and a ricin toxin vaccine candidate.
What Is the Investment Thesis for SNGX?
Soligenix presents a compelling, albeit high-risk, investment opportunity within the biopharmaceutical sector. The company's lead product candidate, SGX301 (HyBryte), has completed Phase III trials for cutaneous T-cell lymphoma, representing a near-term revenue opportunity pending regulatory approval. Positive data from ongoing Phase III trials for SGX942 in oral mucositis could further bolster the company's valuation. The Public Health Solutions segment, while earlier stage, offers long-term potential through its vaccine candidates targeting ricin toxin and COVID-19. However, the company's small market capitalization ($0.01B) and limited number of employees (14) indicate a higher risk profile. Successful commercialization of HyBryte and advancement of other pipeline assets are critical for sustained growth and profitability. Investors should carefully consider the regulatory hurdles, clinical trial outcomes, and competitive landscape before investing.
Based on FMP financials and quantitative analysis
SNGX Key Highlights
SGX301 (HyBryte) has completed Phase III clinical trials for the treatment of cutaneous T-cell lymphoma, representing a potential near-term revenue driver.
- SGX942 is in Phase III clinical trials for the treatment of oral mucositis in head and neck cancer, addressing a significant unmet medical need.
- RiVax, a ricin toxin vaccine candidate, has completed Phase Ia and Ib clinical trials, offering potential in the public health sector.
- The company operates in two segments: Specialized BioTherapeutics and Public Health Solutions, diversifying its pipeline and risk profile.
- Soligenix's focus on rare diseases and unmet medical needs positions it to potentially address critical gaps in the healthcare landscape.
Who Are SNGX's Competitors?
SNGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNGX's Key Strengths?
Late-stage pipeline with potential near-term revenue drivers.
- Focus on rare diseases with unmet medical needs.
- Proprietary drug formulations and technologies.
- Experienced management team with expertise in drug development.
What Are SNGX's Weaknesses?
Small market capitalization and limited financial resources.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Limited commercialization experience.
- High concentration of risk in a few key pipeline assets.
What Could Drive SNGX Stock Higher?
Potential FDA approval of SGX301 (HyBryte) for cutaneous T-cell lymphoma.
- Results from Phase III clinical trials for SGX942 in oral mucositis.
- Continued development of RiVax, a ricin toxin vaccine candidate.
- Advancement of ThermoVax technology for thermostabilizing vaccines.
What Are the Key Risks for SNGX?
Financial-distress signal — its Altman Z-Score of -35.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for key pipeline assets.
- Regulatory delays or rejection of marketing applications.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support research and development.
What Are the Growth Opportunities for SNGX?
- Growth opportunity 1: Successful commercialization of SGX301 (HyBryte) for cutaneous T-cell lymphoma represents a significant near-term growth opportunity. The market for CTCL treatment is estimated to reach several hundred million dollars annually. Securing regulatory approval and establishing a strong market presence could drive substantial revenue growth for Soligenix. The company's novel photodynamic therapy offers a potential advantage over existing treatments, which often have significant side effects.
- Growth opportunity 2: Advancing SGX942 through Phase III clinical trials for oral mucositis in head and neck cancer patients presents another key growth catalyst. Oral mucositis is a common and debilitating side effect of cancer treatment, and there is a significant unmet need for effective therapies. Positive trial results and subsequent regulatory approval could open up a substantial market opportunity for Soligenix.
- Growth opportunity 3: The Public Health Solutions segment, particularly the development of RiVax, a ricin toxin vaccine candidate, offers long-term growth potential. Government contracts and public health initiatives could provide funding and support for the development and deployment of this vaccine. The increasing threat of bioterrorism and emerging infectious diseases underscores the importance of this area.
- Growth opportunity 4: Expanding the application of ThermoVax, a technology for thermostabilizing vaccines, could create new revenue streams and partnerships. Thermostabilization is crucial for vaccine distribution and storage, particularly in developing countries. Collaborating with other vaccine developers and manufacturers could accelerate the adoption of this technology and generate licensing fees and royalties for Soligenix.
- Growth opportunity 5: Exploring new indications for SGX302 in the treatment of mild-to-moderate psoriasis could expand the company's dermatology pipeline. Psoriasis is a chronic inflammatory skin condition affecting millions of people worldwide. Positive results from ongoing clinical trials could lead to regulatory approval and commercialization of SGX302, further diversifying Soligenix's product portfolio.
What Opportunities Does SNGX Have?
- Expanding into new therapeutic areas and geographic markets.
- Partnering with larger pharmaceutical companies for commercialization.
- Securing government funding and grants for public health initiatives.
- Acquiring complementary technologies and assets.
What Threats Does SNGX Face?
- Competition from larger pharmaceutical companies with greater resources.
- Unfavorable clinical trial results or regulatory decisions.
- Patent challenges and intellectual property disputes.
- Changes in healthcare regulations and reimbursement policies.
What Are SNGX's Competitive Advantages?
- Patented drug formulations and technologies.
- Orphan drug designations providing market exclusivity.
- Specialized expertise in developing treatments for rare diseases.
- Established relationships with key opinion leaders and patient advocacy groups.
What Does SNGX Do?
Soligenix, Inc., founded in 1987 and headquartered in Princeton, New Jersey, is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases. Originally named DOR BioPharma, Inc., the company rebranded as Soligenix, Inc. in 2009 to reflect its evolving focus. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment is focused on developing treatments for dermatological and gastrointestinal disorders characterized by significant inflammation. Its lead product candidate, SGX301 (HyBryte), is a novel photodynamic therapy that has completed Phase III clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL). Another key asset in this segment is SGX942, an innate defense regulator technology currently in Phase III clinical trials for the treatment of oral mucositis in head and neck cancer patients. Additionally, this segment includes proprietary formulations of oral beclomethasone 17,21-dipropionate, such as SGX203 for pediatric Crohn's disease and SGX302 for mild-to-moderate psoriasis, both in various stages of clinical development. The Public Health Solutions segment is dedicated to developing vaccines and therapeutics to address public health threats. This segment's pipeline includes RiVax, a ricin toxin vaccine candidate that has completed Phase Ia and Ib clinical trials, SGX943, a therapeutic candidate in pre-clinical development for antibiotic-resistant and emerging infectious diseases, ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines, and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. Soligenix's strategic focus on rare diseases and unmet medical needs positions it to potentially address critical gaps in the healthcare landscape.
What Products and Services Does SNGX Offer?
- Develops SGX301 (HyBryte) for cutaneous T-cell lymphoma.
- Develops SGX942 for oral mucositis in head and neck cancer.
- Formulates oral beclomethasone 17,21-dipropionate for gastrointestinal disorders.
- Develops RiVax, a ricin toxin vaccine candidate.
- Develops SGX943 for antibiotic-resistant and emerging infectious diseases.
- Develops ThermoVax, a technology for thermostabilizing vaccines.
- Develops CiVax, a vaccine candidate for the prevention of COVID-19.
How Does SNGX Make Money?
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved products directly or through partnerships.
What Industry Does SNGX Operate In?
Soligenix operates within the biotechnology industry, which is characterized by high innovation, long development cycles, and significant regulatory oversight. The rare disease market, where Soligenix focuses, is experiencing growth due to increased awareness, orphan drug designations, and unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing therapies for similar indications. Soligenix aims to differentiate itself through its novel photodynamic therapy and vaccine technologies. The overall biotechnology market is projected to continue growing, driven by advancements in genomics, personalized medicine, and biomanufacturing.
Who Are SNGX's Key Customers?
- Patients with rare diseases like cutaneous T-cell lymphoma and oral mucositis.
- Hospitals and clinics that treat these patients.
- Government agencies and public health organizations interested in vaccines and therapeutics for public health threats.
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
Company Profile
Soligenix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Christopher J. Schaber. SNGX has traded publicly since 1994.
Earnings Track Record
Soligenix, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 25.3% above estimates on average.
Financial Health
Soligenix, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.13 places it in the distress zone, a signal of elevated financial risk.
SNGX Valuation & Market Position
With a $5.63M market cap, Soligenix, Inc. sits in the micro-cap segment of the market. Relative to its peer group, SNGX's quantitative score of 28/100 is below the peer average of 76/100.
Forward Outlook
Wall Street analysts project Soligenix, Inc. revenue of about $800K for fiscal 2026, with EPS near $-0.40.
SNGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Late-stage pipeline with potential near-term revenue drivers.
- Focus on rare diseases with unmet medical needs.
- Proprietary drug formulations and technologies.
- Experienced management team with expertise in drug development.
Bear Case
- Small market capitalization and limited financial resources.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Limited commercialization experience.
- High concentration of risk in a few key pipeline assets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SNGX Latest News
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jul 24, 2026
SNGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNGX.
Price Targets
Wall Street price target analysis for SNGX.
SNGX MoonshotScore
What does this score mean?
The MoonshotScore rates SNGX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christopher J. Schaber
CEO
Christopher J. Schaber serves as the CEO of Soligenix, Inc., leading the company's strategic direction and operations. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at various biotech companies, contributing to the advancement of novel therapies. Schaber's expertise spans clinical development, regulatory affairs, and business development, making him well-suited to guide Soligenix through its late-stage clinical programs and potential product launches. His educational background includes advanced degrees in relevant scientific disciplines, providing a strong foundation for his leadership role.
Track Record: Under Christopher J. Schaber's leadership, Soligenix has advanced several key pipeline assets, including SGX301 (HyBryte) and SGX942, through late-stage clinical trials. He has overseen the company's strategic focus on rare diseases and unmet medical needs, positioning it to potentially address critical gaps in the healthcare landscape. Schaber has also been instrumental in securing funding and partnerships to support the company's research and development efforts. His leadership has been marked by a commitment to innovation and a focus on delivering value to patients and shareholders.
Common Questions About SNGX (Healthcare)
What does the AI Score mean for SNGX?
SNGX holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Their pipeline includes therapies for cutaneous T-cell lymphoma …
What does Soligenix, Inc. do?
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and areas of unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops treatments for dermatological and gastrointestinal disorders, including SGX301 (HyBryte) for cutaneous T-cell lymphoma and SGX942 for oral mucositis.
What do analysts say about SNGX stock?
Analyst coverage of Soligenix is limited, reflecting its small market capitalization and early-stage development. However, analysts generally view the company's pipeline as promising, particularly SGX301 (HyBryte) and SGX942. Valuation metrics are highly dependent on the successful commercialization of these assets and the advancement of other pipeline candidates.
What are the main risks for SNGX?
The main risks for Soligenix include the inherent uncertainties associated with drug development, such as unfavorable clinical trial results, regulatory delays, and competition from larger pharmaceutical companies. The company's small market capitalization and limited financial resources also pose risks, as it may need to raise additional capital to fund its research and development activities.
What are the key factors to evaluate for SNGX?
Soligenix, Inc. (SNGX) holds an AI score of 28/100 (low). Soligenix presents a compelling, albeit high-risk, investment opportunity within the biopharmaceutical sector. Not financial advice.
How frequently does SNGX data refresh on this page?
SNGX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNGX's recent stock price performance?
Soligenix, Inc. (SNGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Late-stage pipeline with potential near-term revenue drivers. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNGX overvalued or undervalued right now?
Soligenix, Inc. (SNGX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SNGX before investing?
Before investing in Soligenix, Inc. (SNGX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.